<?xml version="1.0" encoding="utf-8"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title><![CDATA[Medical Industry - Newslocker]]></title><link>https://www.newslocker.com/en-uk/profession/medical-industry/</link><atom:link rel="self" href="https://www.newslocker.com/en-uk/profession/medical-industry/rss/" /><atom:link rel="hub" href="http://pubsubhubbub.appspot.com" /><description><![CDATA[Find your latest Medical Industry news with just one click. Don't miss out on anything happening in your profession!]]></description><language>en-uk</language><copyright>Copyright (C) 2026 newslocker.com</copyright><lastBuildDate>Sun, 25 Oct 2026 19:56:00 +0100</lastBuildDate><item><title><![CDATA[Bon Secours nears $6bn takeover of Bain-backed Surgery Partners]]></title><description><![CDATA[US hospital chain is the latest not-for-profit healthcare provider to seek a large deal]]></description><link>https://www.newslocker.com/en-uk/profession/medical-industry/bon-secours-nears-6bn-takeover-of-bain-backed-surgery-partners/</link><pubDate>Sun, 25 Oct 2026 19:56:00 +0100</pubDate><guid>https://www.newslocker.com/en-uk/profession/medical-industry/bon-secours-nears-6bn-takeover-of-bain-backed-surgery-partners/</guid></item><item><title><![CDATA[Medicare Will Pay $50k for Your Heart Attack. It Should Pay $100 to Prevent It.]]></title><description><![CDATA[(MedPage Today) -- We are currently in a "golden age of medical science," yet in a "dark age of healthcare delivery." An important illustration is the diagnosis and treatment of America's number one cause of death and disability, coronary artery...]]></description><link>https://www.newslocker.com/en-uk/profession/medical-industry/medicare-will-pay-50k-for-your-heart-attack-it-should-pay-100-to-prevent-it/</link><pubDate>Sun, 25 Oct 2026 17:00:00 +0100</pubDate><guid>https://www.newslocker.com/en-uk/profession/medical-industry/medicare-will-pay-50k-for-your-heart-attack-it-should-pay-100-to-prevent-it/</guid></item><item><title><![CDATA[Execution Staff Warned That Christa Pike's IV Site Might Have 'Blown']]></title><description><![CDATA[(MedPage Today) -- Tennessee execution team members failed multiple times to establish working IV lines in Christa Pike's arms before her attempted execution and warned that some of her veins may have ruptured, or "blown," before she was injected...]]></description><link>https://www.newslocker.com/en-uk/profession/medical-industry/execution-staff-warned-that-christa-pikes-iv-site-might-have-blown/</link><pubDate>Sun, 25 Oct 2026 15:00:00 +0100</pubDate><guid>https://www.newslocker.com/en-uk/profession/medical-industry/execution-staff-warned-that-christa-pikes-iv-site-might-have-blown/</guid></item><item><title><![CDATA[Another Unprecedented OS Win in Extensive-Stage SCLC With Tarlatamab Maintenance]]></title><description><![CDATA[(MedPage Today) -- Overall survival (OS) in extensive-stage small-cell lung cancer (ES-SCLC) approached 2 years with tarlatamab (Imdelltra) combination maintenance therapy after first-line chemoimmunotherapy, a large randomized trial showed.<br />
Median...]]></description><link>https://www.newslocker.com/en-uk/profession/medical-industry/another-unprecedented-os-win-in-extensive-stage-sclc-with-tarlatamab-maintenance/</link><pubDate>Sun, 25 Oct 2026 14:41:00 +0100</pubDate><guid>https://www.newslocker.com/en-uk/profession/medical-industry/another-unprecedented-os-win-in-extensive-stage-sclc-with-tarlatamab-maintenance/</guid></item><item><title><![CDATA[SGLT2 Inhibitors Tied to Uptick in Hemoglobin and Hematocrit]]></title><description><![CDATA[(MedPage Today) -- DENVER--Treatment with SGLT2 inhibitors was linked with modest but statistically significant increases in hemoglobin and hematocrit levels across a broad spectrum of patient populations, according to a systematic review and...]]></description><link>https://www.newslocker.com/en-uk/profession/medical-industry/sglt2-inhibitors-tied-to-uptick-in-hemoglobin-and-hematocrit/</link><pubDate>Sun, 25 Oct 2026 14:29:00 +0100</pubDate><guid>https://www.newslocker.com/en-uk/profession/medical-industry/sglt2-inhibitors-tied-to-uptick-in-hemoglobin-and-hematocrit/</guid></item><item><title><![CDATA[Many care services in England have never been inspected by regulator]]></title><description><![CDATA[Backlog of assessment calls into question Andy Burnham’s vow to fix the ‘broken’ system]]></description><link>https://www.newslocker.com/en-uk/profession/medical-industry/many-care-services-in-england-have-never-been-inspected-by-regulator/</link><pubDate>Sun, 25 Oct 2026 06:00:00 +0100</pubDate><guid>https://www.newslocker.com/en-uk/profession/medical-industry/many-care-services-in-england-have-never-been-inspected-by-regulator/</guid></item><item><title><![CDATA[Many care homes in England have never been inspected by regulator]]></title><description><![CDATA[Backlog of assessment calls into question Andy Burnham’s vow to fix the ‘broken’ system]]></description><link>https://www.newslocker.com/en-uk/profession/medical-industry/many-care-homes-in-england-have-never-been-inspected-by-regulator/</link><pubDate>Sun, 25 Oct 2026 06:00:00 +0100</pubDate><guid>https://www.newslocker.com/en-uk/profession/medical-industry/many-care-homes-in-england-have-never-been-inspected-by-regulator/</guid></item><item><title><![CDATA[Tovecimig-Based Doublet Boosts Response and PFS in Advanced Biliary Tract Cancer]]></title><description><![CDATA[(MedPage Today) -- Investigational tovecimig combined with paclitaxel significantly improved the response rate and progression-free survival (PFS) in patients with previously treated advanced or metastatic biliary tract cancer, according to the...]]></description><link>https://www.newslocker.com/en-uk/profession/medical-industry/tovecimig-based-doublet-boosts-response-and-pfs-in-advanced-biliary-tract-cancer/</link><pubDate>Sat, 24 Oct 2026 23:29:00 +0200</pubDate><guid>https://www.newslocker.com/en-uk/profession/medical-industry/tovecimig-based-doublet-boosts-response-and-pfs-in-advanced-biliary-tract-cancer/</guid></item><item><title><![CDATA[Novel ADC Achieves Impressive PFS Advantage in HER2-Low Metastatic Breast Cancer]]></title><description><![CDATA[(MedPage Today) -- Patients with recurrent or metastatic HER2-low breast cancer had dramatic improvement in progression-free survival (PFS) when treated with a novel antibody-drug conjugate (ADC) targeting HER2, a large randomized trial showed...]]></description><link>https://www.newslocker.com/en-uk/profession/medical-industry/novel-adc-achieves-impressive-pfs-advantage-in-her2-low-metastatic-breast-cancer/</link><pubDate>Sat, 24 Oct 2026 23:02:00 +0200</pubDate><guid>https://www.newslocker.com/en-uk/profession/medical-industry/novel-adc-achieves-impressive-pfs-advantage-in-her2-low-metastatic-breast-cancer/</guid></item><item><title><![CDATA[Patient Death Reported in Multiple Sclerosis CAR-T Study]]></title><description><![CDATA[(MedPage Today) -- The investigational CD19-directed chimeric antigen receptor (CAR) T-cell therapy zolacabtagene autoleucel (zola-cel) showed the potential to treat people with highly active relapsing multiple sclerosis (MS) and progressive MS...]]></description><link>https://www.newslocker.com/en-uk/profession/medical-industry/patient-death-reported-in-multiple-sclerosis-car-t-study/</link><pubDate>Sat, 24 Oct 2026 21:19:00 +0200</pubDate><guid>https://www.newslocker.com/en-uk/profession/medical-industry/patient-death-reported-in-multiple-sclerosis-car-t-study/</guid></item><item><title><![CDATA[Atacicpet, Sibeprenlimab Halt Decline in Kidney Function in IgA Nephropathy]]></title><description><![CDATA[(MedPage Today) -- DENVER--Two IgA nephropathy drugs--atacicept (Trutakna) and sibeprenlimab injection (Voyxact)--showed they were able to slow kidney function decline in final phase III trial efficacy analyses.<br />
Atacicept and sibeprenlimab...]]></description><link>https://www.newslocker.com/en-uk/profession/medical-industry/atacicpet-sibeprenlimab-halt-decline-in-kidney-function-in-iga-nephropathy/</link><pubDate>Sat, 24 Oct 2026 21:05:00 +0200</pubDate><guid>https://www.newslocker.com/en-uk/profession/medical-industry/atacicpet-sibeprenlimab-halt-decline-in-kidney-function-in-iga-nephropathy/</guid></item><item><title><![CDATA[RSV Hospitalization May Be Taking a Surprising Mortality Toll, CDC Finds]]></title><description><![CDATA[(MedPage Today) -- WASHINGTON--Nearly one in 10 adults hospitalized with respiratory syncytial virus (RSV) infection died in the hospital or within 30 days of discharge, according to a CDC analysis of eight RSV seasons.<br />
Among 18,301 adults...]]></description><link>https://www.newslocker.com/en-uk/profession/medical-industry/rsv-hospitalization-may-be-taking-a-surprising-mortality-toll-cdc-finds/</link><pubDate>Sat, 24 Oct 2026 20:23:00 +0200</pubDate><guid>https://www.newslocker.com/en-uk/profession/medical-industry/rsv-hospitalization-may-be-taking-a-surprising-mortality-toll-cdc-finds/</guid></item><item><title><![CDATA[Clinician AI Use; Predicting Bad Infant Outcomes in Labor; Donor Heart Distribution]]></title><description><![CDATA[(MedPage Today) -- TTHealthWatch is a weekly podcast from Texas Tech. In it, Elizabeth Tracey, director of electronic media for Johns Hopkins Medicine in Baltimore, and Rick Lange, MD, president of Texas Tech Health El Paso, look at the top medical...]]></description><link>https://www.newslocker.com/en-uk/profession/medical-industry/clinician-ai-use-predicting-bad-infant-outcomes-in-labor-donor-heart-distribution/</link><pubDate>Sat, 24 Oct 2026 20:00:00 +0200</pubDate><guid>https://www.newslocker.com/en-uk/profession/medical-industry/clinician-ai-use-predicting-bad-infant-outcomes-in-labor-donor-heart-distribution/</guid></item><item><title><![CDATA[An Accurate Census Protects Our Health]]></title><description><![CDATA[(MedPage Today) -- As a physician, I take care of the individual patient in front of me. As a public health leader, communities are my patients. I ask: Who needs care but is not getting it? Where should we focus resources to prevent vaccine-preventable...]]></description><link>https://www.newslocker.com/en-uk/profession/medical-industry/an-accurate-census-protects-our-health/</link><pubDate>Sat, 24 Oct 2026 18:00:00 +0200</pubDate><guid>https://www.newslocker.com/en-uk/profession/medical-industry/an-accurate-census-protects-our-health/</guid></item><item><title><![CDATA[Health Insurance Costs Keep Climbing for American Workers, New Survey Finds]]></title><description><![CDATA[(MedPage Today) -- People who rely on employer-sponsored health insurance paid more for their coverage this year, with employees at small businesses and their employers especially squeezed by the surging costs, according to a new survey by healthcare...]]></description><link>https://www.newslocker.com/en-uk/profession/medical-industry/health-insurance-costs-keep-climbing-for-american-workers-new-survey-finds/</link><pubDate>Sat, 24 Oct 2026 16:00:00 +0200</pubDate><guid>https://www.newslocker.com/en-uk/profession/medical-industry/health-insurance-costs-keep-climbing-for-american-workers-new-survey-finds/</guid></item><item><title><![CDATA[Endovascular Therapy Eyed for Milder Strokes, Later Time Window]]></title><description><![CDATA[(MedPage Today) -- Endovascular therapy (EVT) made promising forays into milder and later-presenting large vessel occlusion (LVO) strokes in a pair of multicenter, open-label trials from China.<br />
In the MILD-MT trial of people with mild acute ischemic...]]></description><link>https://www.newslocker.com/en-uk/profession/medical-industry/endovascular-therapy-eyed-for-milder-strokes-later-time-window/</link><pubDate>Sat, 24 Oct 2026 03:40:00 +0200</pubDate><guid>https://www.newslocker.com/en-uk/profession/medical-industry/endovascular-therapy-eyed-for-milder-strokes-later-time-window/</guid></item><item><title><![CDATA[Chinese Drug Shows Benefit in HER2-Low Breast Cancer]]></title><description><![CDATA[(MedPage Today) -- An investigational antibody-drug conjugate (ADC) significantly reduced the risk of disease progression or death in patients with HER2-low metastatic breast cancer, a Chinese phase III trial showed.<br />
The drug, trastuzumab rezetecan...]]></description><link>https://www.newslocker.com/en-uk/profession/medical-industry/chinese-drug-shows-benefit-in-her2-low-breast-cancer/</link><pubDate>Fri, 23 Oct 2026 23:13:00 +0200</pubDate><guid>https://www.newslocker.com/en-uk/profession/medical-industry/chinese-drug-shows-benefit-in-her2-low-breast-cancer/</guid></item><item><title><![CDATA[Type of Menopause Hormone Therapy Tied to Small Autoimmune Disease Risk]]></title><description><![CDATA[(MedPage Today) -- Estrogen-only menopausal hormone therapy was associated with a slightly higher incidence of autoimmune disease compared with estrogen-progestogen therapy, a retrospective cohort study suggested.<br />
Among over 100,000 women taking...]]></description><link>https://www.newslocker.com/en-uk/profession/medical-industry/type-of-menopause-hormone-therapy-tied-to-small-autoimmune-disease-risk/</link><pubDate>Fri, 23 Oct 2026 23:08:00 +0200</pubDate><guid>https://www.newslocker.com/en-uk/profession/medical-industry/type-of-menopause-hormone-therapy-tied-to-small-autoimmune-disease-risk/</guid></item><item><title><![CDATA[Supplement Shows Promise for Improving Cancer-Related Cognitive Impairment]]></title><description><![CDATA[(MedPage Today) -- Cancer-related cognitive impairment (CRCI) in breast cancer survivors improved significantly after treatment with the glutamate regulator oxaloacetate, a preliminary single-arm clinical study showed.<br />
All 16 evaluable patients...]]></description><link>https://www.newslocker.com/en-uk/profession/medical-industry/supplement-shows-promise-for-improving-cancer-related-cognitive-impairment/</link><pubDate>Fri, 23 Oct 2026 22:45:00 +0200</pubDate><guid>https://www.newslocker.com/en-uk/profession/medical-industry/supplement-shows-promise-for-improving-cancer-related-cognitive-impairment/</guid></item><item><title><![CDATA[Infants' Maternal Measles Protection May Not Last Until First MMR Dose]]></title><description><![CDATA[(MedPage Today) -- WASHINGTON--At 6 months of age, most U.S. infants no longer had detectable levels of maternal neutralizing antibodies for measles, potentially leaving them at risk of an infection months before their first dose of the measles...]]></description><link>https://www.newslocker.com/en-uk/profession/medical-industry/infants-maternal-measles-protection-may-not-last-until-first-mmr-dose/</link><pubDate>Fri, 23 Oct 2026 21:14:00 +0200</pubDate><guid>https://www.newslocker.com/en-uk/profession/medical-industry/infants-maternal-measles-protection-may-not-last-until-first-mmr-dose/</guid></item></channel></rss>